Roxatidine acetate

Roxatidine acetate
Clinical data
Routes of
ATC code A02BA06 (WHO)
Pharmacokinetic data
Bioavailability 80–90%
Protein binding 5–7%
Metabolism Hepatic deacetylation
Minor involvement of CYP2D6 and CYP2A6
Biological half-life 5–7 hours
Excretion Renal
CAS Number 78628-28-1 N
PubChem (CID) 5105
DrugBank DB08806 YesY
ChemSpider 4926 YesY
KEGG D08495 YesY
Chemical and physical data
Formula C19H28N2O4
Molar mass 348.437 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]

Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]

It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]


This article is issued from Wikipedia - version of the 7/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.